PCVX vs VRTX
Vaxcyte, Inc. vs Vertex Pharmaceuticals — AI-powered side-by-side comparison
PCVX
Vaxcyte, Inc.
66
Insufficient Data
VS
VRTX
Vertex Pharmaceuticals
66
Buy
| Metric | PCVX | VRTX |
|---|
| AI Score |
66
|
66
|
| Price |
$59.22
|
$529.70
|
| P/E Ratio |
-7.75×
|
30.58×
|
| ROE |
-28.5%
|
21.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
0.0%
|
86.0%
|
| Debt / Equity |
0.04×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
65.6
|
80.4
|
| Beta |
1.21
|
0.305
|
| Expected Upside |
—
|
+1.5%
|
AI Committee View
Current Innellis committee reasoning for PCVX versus VRTX.
The committee scores are tied.
PCVX and VRTX both score 66/100.
PCVX Committee View
67% agreement
3 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Price structure (LH_LL) contradicts the uptrend -- mixed signals — Technical
VRTX Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 23.3% shows genuine earnings power backing the valuation — Value
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- P/E of 29.0 is moderate-to-rich — Value
- Price-to-book of 6.2x prices in significant intangible value — Value
- RSI at 80 is in overbought territory — Technical